{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:53:34Z","timestamp":1786978414149,"version":"build-2736575974"},"reference-count":33,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2019,11,20]],"date-time":"2019-11-20T00:00:00Z","timestamp":1574208000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010643","name":"Cidara Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010643","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bpspubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology Res &amp; Perspec"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Rezafungin acetate is a novel echinocandin in clinical development for prevention and treatment of invasive fungal infections. Rezafungin is differentiated by a pharmacokinetic\/pharmacodynamic (PK\/PD) profile that includes a long half\u2010life allowing once\u2010weekly administration, front\u2010loaded plasma drug exposures associated with antifungal efficacy, and penetration into deep\u2010seated infections, such as intra\u2010abdominal abscesses. In this series of in vivo studies, rezafungin demonstrated efficacy in the treatment of neutropenic mouse models of disseminated candidiasis, including infection caused by azole\u2010resistant\n                    <jats:italic>Candida albicans<\/jats:italic>\n                    , and aspergillosis. These results contribute to a growing body of evidence demonstrating the antifungal efficacy and potential utility of rezafungin in the treatment of invasive fungal infections.\n                  <\/jats:p>","DOI":"10.1002\/prp2.546","type":"journal-article","created":{"date-parts":[[2019,11,20]],"date-time":"2019-11-20T03:35:27Z","timestamp":1574220927000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Rezafungin treatment in mouse models of invasive candidiasis and aspergillosis: Insights on the PK\/PD pharmacometrics of rezafungin efficacy"],"prefix":"10.1002","volume":"7","author":[{"given":"Lynn","family":"Miesel","sequence":"first","affiliation":[{"name":"Eurofins Panlabs Taipei Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun\u2010Yuan","family":"Lin","sequence":"additional","affiliation":[{"name":"Eurofins Panlabs Taipei Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8676-6717","authenticated-orcid":false,"given":"Voon","family":"Ong","sequence":"additional","affiliation":[{"name":"Cidara Therapeutics, Inc San Diego CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,11,20]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1086\/651263"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1086\/651262"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/myc.12330"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/ja.2016.89"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofw172.1542"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00701-16"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01626-16"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01627-16"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2017.10.021"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01572-18"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02154-17"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkw214"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx448"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00758-17"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01009-17"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02614-17"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-6-55"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01541-16"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02045-16"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2017.03.028"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dky280"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/cmi.12640"},{"key":"e_1_2_10_24_1","volume-title":"Rezafungin clinical safety and efficacy in the treatment of candidemia and\/or invasive candidiasis: combined results from the STRIVE Phase 2 trial Parts A and B","author":"Thompson GR","year":"2019"},{"key":"e_1_2_10_25_1","volume-title":"Clinical efficacy and safety of rezafungin (CD101): results from STRIVE, a randomized, double\u2010blind, multicenter, phase 2 study in the treatment of candidemia and\/or invasive candidiasis","author":"Thompson GR","year":"2018"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofw172.1521"},{"key":"e_1_2_10_27_1","volume-title":"EUCAST susceptibility testing of rezafungin (CD101): activity against Candida auris","author":"Arendrup MC","year":"2018"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2016.07.008"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw691"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6544e1"},{"key":"e_1_2_10_31_1","volume-title":"Rezafungin is efficacious against invasive aspergillosis caused by azole-resistant Aspergillus fumigatus harboring the TR34\/L98H mutation","author":"Wiederhold N","year":"2019"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dky280"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01165-19"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dky153"}],"container-title":["Pharmacology Research &amp; Perspectives"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/prp2.546","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/prp2.546","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/prp2.546","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T00:24:05Z","timestamp":1692663845000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1002\/prp2.546"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,20]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["10.1002\/prp2.546"],"URL":"https:\/\/doi.org\/10.1002\/prp2.546","archive":["Portico"],"relation":{},"ISSN":["2052-1707","2052-1707"],"issn-type":[{"value":"2052-1707","type":"print"},{"value":"2052-1707","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,20]]},"assertion":[{"value":"2019-02-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-10-24","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-11-20","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00546"}}